New hope for advanced cervical cancer: experimental drug takes on chemo in major trial
NCT ID NCT07418749
First seen Feb 22, 2026 · Last updated Apr 23, 2026 · Updated 4 times
Summary
This study tests a new drug called SHR-A2102 against standard chemotherapy in people with recurrent or metastatic cervical cancer that has not responded to platinum-based chemo and immunotherapy. About 398 participants will be randomly assigned to receive either SHR-A2102 or a doctor-chosen chemotherapy. The main goal is to see if SHR-A2102 helps people live longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.